Gene fusions involving members of the FET and CREB families have been increasingly recognized as recurrent oncogenic events, driving oncogenesis in anatomically, phenotypically, and genetically diverse mesenchymal neoplasms occurring in soft tissue, bone, and visceral sites [4]. This evidence concerns the gene CREB1 and mesenchymal cell neoplasm.